Program Director's Choice from SABCS2025 - Part 2: Sacituzumab Govitecan for Endocrine Therapy-refractory Advanced Breast Cancers

ADA/EASD Consensus Report on the Management of Type 2 Diabetes - report from EASD 2026

13 Okt 2026

Dr. John Bernard Buse presents key updates from the joint ADA/EASD consensus report on the management of type 2 diabetes at the EASD 2026 Congress. This brief highlights updated clinical guidelines, person-centered management strategies, holistic care approaches, and evidence-based recommendatio ...

00:06:58

Retatrutide in Adults with Obesity and Type 2 Diabetes: Phase 3 TRIUMPH-2 Trial - report from EASD 2026

13 Okt 2026

Dr. Stefano Del Prato presents key findings from the Phase 3 TRIUMPH-2 trial evaluating retatrutide at the EASD 2026 Congress. This brief highlights clinical evidence on the glycemic efficacy, weight reduction outcomes, and safety profile of triple receptor agonism in adults living with obesity ...

00:02:46

Beyond Weight Loss: A Biology-Driven Approach to Metabolic Health – Obesity as a Systemic Disease: From Adiposity to Metabolic Dysfunction - report from EASD 2026

13 Okt 2026

Dr. Paolo Sbraccia presents key insights into viewing obesity as a systemic disease and adopting a biology-driven approach to metabolic health at the EASD 2026 Congress. This brief highlights the pathophysiological progression from adiposity to systemic metabolic dysfunction, emphasizing targete ...

00:06:21

Renal Outcomes and Cardiorenal Mechanisms in Type 2 Diabetes: Highlights from the FLOW and ACHIEVE-4 Trials - report from EASD 2026

13 Okt 2026

Dr. Katherine Tuttle presents key insights on cardiorenal protection in type 2 diabetes at the EASD 2026 Congress, drawing from both the FLOW and ACHIEVE-4 trials. This brief highlights novel proteomic biomarker analyses explaining the pathways of kidney protection in FLOW, alongside clinical da ...

00:04:59